Children's oncology group's 2013 blueprint for research: Bone tumors

Richard Gorlick, Katherine Janeway, Stephen Lessnick, R. Lor Randall, Neyssa Marina

Research output: Contribution to journalReview articlepeer-review

129 Scopus citations


In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.

Original languageEnglish (US)
Pages (from-to)1009-1015
Number of pages7
JournalPediatric Blood and Cancer
Issue number6
StatePublished - Jun 2013
Externally publishedYes


  • Blueprint
  • Bone sarcoma
  • Ewing sarcoma
  • Osteosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Children's oncology group's 2013 blueprint for research: Bone tumors'. Together they form a unique fingerprint.

Cite this